Back to Investors
EP

Ed Parkinson

Angel

Portfolio

1

companies


Portfolio companies

Antiverse

Antiverse

Antiverse develops AI-designed therapeutic antibodies for challenging disease targets using computational platforms and in-house laboratories.


Team

EP

Ed Parkinson

lead investor for the syndicate of Angel Investors


Recent investments

Seed
£1.4M

The seed round was supported by a syndicate of investors including the Development Bank of Wales and the UKI2S Innovate Accelerator to fund platform development and laboratory expansion.

"Our investors recognise the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support."
— Murat Tunaboylu, Co-Founder and CEO